Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism - RE-MEDY and RE-SONATE


Dabigatran is an oral direct thrombin inhibitor that has been shown to be noninferior to warfarin for the initial treatment of venous thromboembolism (VTE) (6 months). Two parallel complementary trials were designed for extended duration of treatment in these patients: RE-MEDY comparing dabigatran to warfarin, and RE-SONATE comparing dabigatran to placebo.